Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model
Keywords: animals, biological models, blood proteins, Caco-2 cells, dogs, erectile dysfunction, humans, liver microsomes, phosphodiesterase 5, ratsSoftware: GastroPlus®Publication: Acta Pharmacol Sin
Aim
TPN729MA is a novel selective PDE5 inhibitor currently under clinical development in China for the treatment of erectile dysfunction. In this study we characterized its preclinical pharmacokinetics (PK) and predict its human PK using a physiologically based pharmacokinetic (PBPK) model.
